Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25612924 | 0.85 | THRA (0.35) | THRATHRB | |
| SCHEMBL25612923 | 0.85 | THRA (0.35) | THRATHRB | |
| SCHEMBL25612921 | 0.83 | THRA (0.34) | THRATHRB | |
| SCHEMBL25481604 | 0.83 | — | — | |
| SCHEMBL24005794 | 0.81 | — | — | |
| SCHEMBL25612930 | 0.81 | THRA (0.33) | THRATHRB | |
| SCHEMBL25623224 | 0.81 | THRA (0.33) | THRATHRB | |
| SCHEMBL24006076 | 0.80 | PLG (0.32) | — | |
| SCHEMBL25468659 | 0.79 | — | — | |
| SCHEMBL24005855 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| WO-2021223736-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | THRA 4698/4885THRB 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.